| Wissenschaftl. Titel | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy, Safety and Pharmacokinetics of Lebrikizumab Compared to Placebo in Participants 6 Months to <18 Years of Age with Moderate-to-Severe Atopic Dermatitis |
| Erkrankung |
Kinder:
Hauterkrankungen
|
| weitere Prüfzentren | |
| Kurzprotokoll | Kurzprotokoll |
erstellt 25.01.2024 Admin03
geändert 27.08.2024 Admin07